| Date | Title | Description |
| 03.06.2025 | This biotech stock rallying on cancer treatment data has more room to run, analysts say | - |
| 15.05.2019 | Health And Genomic Data Platform Company LunaPBC Secures $4.6 Million | Genomic and health data platform company LunaPBC announced that it has raised $4.6 million in a new round of funding. Including this round of funding, LunaPBC has raised $7.6 million total. ARCH Venture Partners, Bain Capital Ventures, F-Pr... |
| 31.07.2018 | What corporate culture characteristics make or break startups? | BIOCOM and Slone Partners co-hosted an event called Culture as Cornerstone: Bay Area Perspective – Activating Senior Executives To Build Thriving Cultural Environments.” The focus was on workplace culture – what defines it, what builds it, ... |
| 30.12.2017 | Why do many IVD companies face an uphill battle with payers for reimbursement? | To understand why so many companies have faced an uphill battle with payers for reimbursement of their products, it’s essential to consider how these decisions are made. FDA approval or clearance is just one factor influencing payer decisio... |
| 04.08.2017 | Learning from failure: What Theranos, Interleukin Genetics, & Courtagen can teach us about IVDs | Developing and commercializing an in vitro diagnostic (IVD) is a complex enterprise involving numerous tasks accomplished by a variety of specialized and knowledgeable individuals. Generally, the process can be broken down into product conc... |
| 28.04.2017 | Biopharma just can’t get enough of Epic Sciences | So what’s all the fuss about?
Epic is a liquid biopsy company that generates diagnostic information by screening a patient’s blood. It’s a high buzz field, with companies ranging from Freenome to Thermo Fisher Scientific to Guardant Health ... |
| 13.10.2014 | Invitae raises $120M for its $1,500 gene sequencing test | Genomics will someday be your doctor’s major weapon for keeping you healthy throughout your life.
The San Francisco-based genetics company Invitae is pushing hard toward making that a reality. The company has developed a test that sequences... |
| 13.10.2014 | Invitae raises $120M for its $1,500 gene sequencing test | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Genomics will someday be your doctor’s major weap... |
| 08.10.2013 | Through molecular analysis, Virginia healthcare startup hopes to bring personalized cancer treatment to stage-4 patients | The startup claims to be the “only company that safeguards biopsy quality for analysis and takes into account proteomics, genomics and your past medical history.”
Perthera uses this information to create a report for stage-four cancer patie... |
| 14.05.2013 | Genetic testing, cancer and preventive surgery: Not just in breast cancer | Angeline Jolie’s disclosure of her double mastectomy has drawn the mainstream media’s attention to genetic testing, a recent medical advancement with huge, albeit challenging, implications.
Many experts predict that genetic testing is on it... |
| 22.01.2013 | Genomics startup gets $3M to usher in new era of ‘personalized medicine’ | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
The cost of sequencing the human genome has plumm... |
| 22.01.2013 | Genomics startup gets $3M to usher in new era of ‘personalized medicine’ | The cost of sequencing the human genome has plummeted. But how will this benefit doctors and patients?
Biomedical researchers hope to harness data about the human gene pool to usher a new era of “personalized medicine,” which could lead to ... |
| 29.11.2012 | The cloud ate my data! Health entrepreneurs say vendors should be liable | At CloudBeat, the healthcare panel kicked off with a harrowing statistic. The vast majority of breast cancer sufferers will not benefit from chemotherapy. And yet, most patients today receive this highly invasive treatment.
According to gen... |
| 29.11.2012 | The cloud ate my data! Health entrepreneurs say vendors should be liable | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
At CloudBeat, the healthcare panel kicked off wit... |
| 04.04.2012 | Kauffman Life Science Ventures Summit to share tips for startups | To guide entrepreneurs in laying out a plan for creating, delivering and capturing value with their products and overcoming other entrepreneurial challenges, The Ewing Marion Kauffman Foundation is hosting The Life Science Ventures Summit o... |
| 02.04.2012 | What venture capitalists look for in personalized medicine investments | “Because they can offer the right product, they can take away unnecessary costs,” Kocher said. “And in healthcare, that’s what we really need to do.”
Personalized medicine will help doctors determine what to treat, how to treat and how much... |
| 07.10.2009 | Schering-Plough launches schizophrenia, bi-polar disorder drug after buying maker | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| 25.10.2007 | XDx marks a spot: An $86M IPO for gene-expression diagnostics | (UPDATED: See below.)
When XDx yesterday filed to raise up to $86.3 million in an IPO, the Brisbane, Calif., company joined just a handful of similar molecular-diagnostic companies to test the public markets. XDx specializes in a new type o... |
| - | Kauffman Life Science Ventures Summit to share tips for startups | This post is sponsored by Kauffman Foundation.
Second only to funding, establishing a sustainable revenue model was one of the biggest concerns cited by early stage digital health entrepreneurs in a 2011 survey. And with the life science la... |
| - | Through molecular analysis, Virginia healthcare startup hopes to bring personalized cancer treatment to stage-4 patients | While many point to genetic testing as the major breakthrough for personalized cancer treatment, a startup in Virginia thinks that’s only a third of the equation.
“Genes tell you what could be and proteins tell you what is,” Perthera Co-Fou... |
| - | What venture capitalists look for in personalized medicine investments | Companies like Starbucks (NASDAQ:SBUX), Amazon.com (NASDAQ:AMZN) and Apple (NASDAQ:AAPL) aren’t healthcare companies, but one venture capitalist believes their example can guide personalized medicine.
Bob Kocher, a partner at venture capita... |
| - | What corporate culture characteristics make or break startups? | We’re soldiers now in the culture war. We’re soldiers now, but we don’t know what it’s for. — Arcade Fire
I am fortunate I get to moderate a lot of interesting panel discussions. They are usually about healthcare or investing and occasional... |
| - | Why do many IVD companies face an uphill battle with payers for reimbursement? | The demise of Courtagen Life Sciences earlier this year brought increased attention to a long-standing problem for the in vitro diagnostic (IVD) industry, particularly for genetic tests: getting reimbursement from third-party payers is chal... |
| - | Schering-Plough launches schizophrenia, bi-polar disorder drug after buying maker | CLEVELAND, Ohio – Sometimes acquiring other drugmakers is the way to fill your company’s development pipeline with new drugs.
Fred Hassan, chairman and chief executive of Schering-Plough Corp., told attendees of the Cleveland Clinic’s 2... |
| - | Biopharma just can’t get enough of Epic Sciences | Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round, a whopping 42 industry partnerships and over 200 clinical trials in the works, all built around its novel liquid biopsy... |
| - | Learning from failure: What Theranos, Interleukin Genetics, & Courtagen can teach us about IVDs | In the aftermath of the Theranos downfall, dozens of pundits have performed virtual autopsies of where CEO Elizabeth Holmes went wrong, generally highlighting a lack of full disclosure about the technology its labs were using. In the beginn... |
| - | Genetic testing, cancer and preventive surgery: Not just in breast cancer | Angeline Jolie’s disclosure of her double mastectomy has drawn the mainstream media’s attention to genetic testing, a recent medical advancement with huge, albeit challenging, implications.
Many experts predict that genetic testing is on it... |
